Italia markets closed

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,9900+0,0100 (+0,34%)
Alla chiusura: 04:00PM EDT
2,9700 -0,02 (-0,67%)
Dopo ore: 05:42PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,9800
Aperto2,9700
Denaro2,9800 x 200
Lettera3,0100 x 200
Min-Max giorno2,9400 - 3,0800
Intervallo di 52 settimane2,6700 - 9,2500
Volume116.230
Media Volume293.979
Capitalizzazione83,477M
Beta (5 anni mensile)-0,02
Rapporto PE (ttm)N/D
EPS (ttm)-1,6500
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A16,50
  • GlobeNewswire

    Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

    Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophre

  • GlobeNewswire

    Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

    CUPERTINO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will both present and participate in a conference panel at the H.C. Wainwright 25th Annual G

  • GlobeNewswire

    Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

    - 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervou